
Verona Pharma (VRNA) Stock Forecast & Price Target
Verona Pharma (VRNA) Analyst Ratings
Bulls say
Verona Pharma PLC has demonstrated significant momentum, with Ohtuvayre prescriptions increasing by over 35% each month in the fourth quarter of 2024, contributing to a revised full-year 2025 revenue forecast of $265 million. The company's impressive sales ramp and a fourth-quarter revenue total of approximately $42 million, which exceeded earlier projections, suggest a strong potential for long-term growth in Ohtuvayre's market presence. Additionally, with sufficient cash resources projected to support operations towards sustainable profitability, Verona Pharma is well-positioned to capitalize on the anticipated growth of its product candidate, ensifentrine, particularly in revenue streams from new markets not yet included in current valuations.
Bears say
Verona Pharma PLC faces significant challenges that contribute to a negative outlook on its stock, primarily centered around the anticipated commercial uptake of its product candidate, Ensifentrine, which may be slower than projected in both the U.S. and European markets. Additional concerns include potential competitive pressures that could hinder the optimization of Ensifentrine's value outside the U.S., as well as risks associated with the execution of partnerships aimed at enhancing its global market presence. Furthermore, the company may face the possibility of negative trial results for Ensifentrine, alongside the risk of long-term dilution, adding to the uncertainty surrounding its financial stability.
This aggregate rating is based on analysts' research of Verona Pharma and is not a guaranteed prediction by Public.com or investment advice.
Verona Pharma (VRNA) Analyst Forecast & Price Prediction
Start investing in Verona Pharma (VRNA)
Order type
Buy in
Order amount
Est. shares
0 shares